POLARCOOL AB
NNGM:POLAR1.09
SEK
-0.41
(-27.33%)
ISIN
SE0023467162
Return %
Stock
S&P 500
1Y
-71.78
14.20
3Y
-93.98
81.12
5Y
-99.13
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Erik Andersson
- Full Time Employees
- 3
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Lund Sweden
- IPO Date
- Nov 27, 2018
- Website
- polarcap.com
- Similar Companies
- Business
- PolarCool AB (publ) is a Sweden-based medical technology company that develops, manufactures, and commercializes portable therapeutic hypothermia and brain cooling solutions designed to mitigate the consequences of concussions and mild traumatic brain injuries (mTBI) in sports, emergency care, and clinical environments. The company operates within the medical device and sports medicine sectors, focusing on evidence-based acute cooling protocols to reduce secondary brain damage, alleviate post-concussion symptoms, and shorten recovery times for athletes and patients. The company's core product portfolio is anchored by the PolarCap System, a proprietary, portable medical cooling technology utilized for acute head and neck cooling immediately following concussive events. The company's systematic product and service offerings comprise: the PolarCap cooling unit, a mobile refrigeration device engineered to regulate and circulate chilled fluid at controlled temperatures; specialized silicone cooling caps and insulated neoprene head covers configured to facilitate direct and uniform thermal transfer to the scalp and neck; disposable hygiene caps and interface accessories ensuring clinical-grade sanitation across multi-user environments; system monitoring software and digital tracking tools for operational monitoring; clinical training and protocol integration services for club physicians, athletic trainers, and emergency responders; and ongoing maintenance, calibration, and warranty support services. PolarCool AB serves professional and amateur sports organizations, collegiate athletic programs, national sports governing bodies, rehabilitation centers, and clinical research institutions. Its target markets span contact and collision sports, including rugby, ice hockey, football, equestrian sports, handball, and martial arts. The company maintains commercial presence and distribution networks across Europe, including Sweden, the United Kingdom, France, Germany, Switzerland, Austria, and broader international regions. In recent developments, PolarCool AB has accelerated its commercial rollouts and strategic market expansion across top-tier international sports leagues. The company has secured multi-year partnership and supply agreements with high-profile organizations across European rugby and ice hockey, including clubs in the United Kingdom's Premiership Rugby, the French Top 14 and Pro D2, Germany's Deutsche Eishockey Liga (DEL), and the Swiss National League. To support international growth, the company has focused on regulatory positioning under the European Union Medical Device Regulation (MDR) and initiated strategic preparations and clinical evaluation workflows for market entry into the United States. Additionally, PolarCool has completed capital financing measures and rights issues to fund commercialization efforts, strengthen its distribution infrastructure, and support published clinical studies demonstrating the long-term health and financial benefits of early post-injury cooling. PolarCool AB was founded in 2013 as a spin-off from BrainCool AB and is headquartered in Lund, Sweden. The company's shares are listed on the Nordic Growth Market (NGM) under the ticker symbol POLAR.